European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) label. The label update incorporates data showing that Wegovy,
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...
Hope Unlimited Ministries will have its annual fundraising event featuring Point of Grace on Thursday, Oct. 17. This event ...
And happiness—or the lack of it—may affect our heart health, according to research published on September 18, 2024 ...
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
GlobalData on MSN1d
FDA lists Astellas’ digital health solution for heart failure managementThe US Food and Drug Administration (FDA) has listed Astellas Pharma’s non-invasive digital health solution, DIGITIVA, ...
Astellas Pharma announces US FDA listing of DIGITIVA for the management of heart failure: Tokyo Friday, September 20, 2024, 11:00 Hrs [IST] Astellas Pharma Inc. announced that DIG ...
Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In ...
A gran of two was forced to wait more than 25 hours in a hospital corridor after suffering a suspected heart attack. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback